The Role of Small Molecule NMR in Medicinal Chemistry

In this on-demand webinar, Kathleen Farley, Senior Principal Scientist, R&D, Pfizer Inc, describes how nuclear magnetic resonance (NMR) spectroscopy is integrated into the Pfizer drug discovery pipeline and how the technique is used.

Webinar Overview

Since its early days, nuclear magnetic resonance (NMR) has played an important role in the pharmaceutical industry. NMR is traditionally used by medicinal chemists for structure elucidation of both synthesized molecules and active compounds isolated from natural sources. However, it can also be a valuable tool for reaction monitoring, the characterization of solution conformations, the investigation of metabolites, hit-to-lead optimization and quantitation.

In this on-demand webinar, Kathleen Farley, Senior Principal Scientist, R&D, Pfizer Inc, describes how NMR spectroscopy is integrated into the Pfizer drug discovery pipeline and how the technique is used in a walk-up environment by medicinal chemists and NMR scientists to solve challenging drug discovery problems.

Additionally, Anna Codina, Director Pharmaceutical Business Unit, Bruker BioSpin, finishes the webinar by presenting new additions to the NMR instrumentation family that make the technique available to a wider audience, overcoming some of the current cost concerns. This expansion includes both affordable high-resolution and benchtop instrumentation.

Thursday 02 December 2021

04:00 PM CET


Kathleen Farley
Senior Principal Scientist, R&D Pfizer Inc

Kathleen Farley is a Senior Principal Scientist in the R&D division at Pfizer Inc with over 30 years of experience in the pharmaceutical industry providing NMR support for Medicinal Chemistry research. She has taught the American Chemical Society (ACS) NMR course, “1D and 2D NMR Spectroscopy: Structure Determination of Small Molecule Organic Compounds” with Greg Walker for the last 10 years. Kathleen also has over 40 publications including a book chapter and two patents. Her current research includes the structural characterisation of small molecules and peptides using residual dipolar couplings.

Dr. Anna Codina

Director Pharmaceutical Business Unit, Bruker BioSpin

Anna has a degree in Chemistry and a PhD in Protein NMR from the University of Barcelona, Spain. She undertook her post-doc in protein NMR at the MRC Laboratory of Molecular Biology in Cambridge, UK, and following that worked in the Analytical R&D department of Pfizer for eight years, becoming proficient in low level impurity structure elucidation, reaction monitoring, qNMR and the preparation of regulatory documentation.

She received a Pfizer Worldwide Achievement Award for the implementation of reaction monitoring by NMR in an open access environment.

She joined Bruker in 2011 as Material Characterisation Laboratory Manager and she is now the Director of the Pharmaceutical Business Unit at Bruker BioSpin.


Input value is invalid.

Are you already in contact with your Bruker representative regarding any product inquiries?

We constantly want to improve our service for our customers. In answering the following question you help us to serve your needs even better in the future: What best describes your situation?

By ticking this box, I agree to receive, from time to time, emails from Bruker and its affiliates within the Bruker Group on upcoming events, webinars, our products and services, surveys and Bruker's corporate news.
I can unsubscribe at any time, by contacting Bruker or clicking on the opt-out link in the email if available. For more information on the processing of your personal data, please check Bruker’s Privacy Policy. 

By submitting this form I agree my personal data will be used to process my registration to the webinar. I have read and accepted the Bruker Website Privacy Notice ( and I agree to the Terms of Use ( of the Bruker website.

Already registered and lost your invitation link?

Thank you. The invitation link has been resent.